Research programme: somatostatin analogues - ArdanaAlternative Names: Somatostatin analogues research programme - Ardana
Latest Information Update: 25 Oct 2006
At a glance
- Originator Ardana Bioscience
- Mechanism of Action Somatotropin receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 25 Aug 2002 Europeptides has been acquired from Zentaris AG by Ardana Bioscience
- 19 May 2000 Preclinical development for Cancer in France (Unknown route)